{"success":true,"data":{"pressRelease":{"id":"4900","rtpr_id":"nPn5ds3x7a","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky","author":"PR Newswire","published_at":"2026-04-22T13:00:51.734Z","article_body":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nCritical Information: $1.98 Per Share Loss Quantifies Alleged Investor Damages\nAfter FDA Warning Letter\n\nNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds\npurchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities of a pending\nsecurities class action.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nTHE CASE: A class action seeks to recover damages for investors who purchased\nIBRX securities between January 19, 2026 and March 24, 2026.\n\nYOUR OPTIONS: You may be entitled to compensation without payment of any\nout-of-pocket fees. See if you can recover losses from your IBRX investment\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669914-18&h=3450116832&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185027%26wire%3D4&a=See+if+you+can+recover+losses+from+your+IBRX+investment)\n or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\nOn March 24, 2026, ImmunityBio shares lost $1.98 per share, falling 21% to\nclose at $7.42. The day prior, shares had traded as high as $9.40. The\ncollapse followed the publicization of an FDA Warning Letter that determined\nImmunityBio's promotional communications about its bladder cancer drug ANKTIVA\nwere false or misleading and misbranded the product in violation of federal\nlaw.\n\nThe March 24 Market Repricing\n\nThe market removed artificial inflation from IBRX shares after the FDA Warning\nLetter revealed that the Company's Executive Chairman had made claims about\nANKTIVA that the agency found to be unsupported by clinical data. The FDA\ndetermined that a TV advertisement and a January 19, 2026 podcast appearance\ncreated \"a misleading impression that Anktiva, a treatment for a certain type\nof bladder cancer, can cure and even prevent all cancer.\" The filing states\nthat the FDA called these violations \"concerning from a public health\nperspective\" because they \"grossly misrepresent the benefits of Anktiva.\"\n\nHow the Market Absorbed the Corrective Disclosure\n\n * IBRX shares traded at $9.40 on March 23, 2026, the last trading day before the\nFDA Warning Letter became public\n * Shares opened sharply lower on March 24 and closed at $7.42, a single-day loss\nof $1.98 per share\n * The 21% decline reflected the market's rapid reassessment of the Company's\npromotional claims about ANKTIVA\n * Bloomberg published an article titled \"ImmunityBio Plunges After Getting FDA\nWarning on Cancer Drug,\" amplifying the corrective information across\nfinancial media\n * The FDA letter was dated March 13, 2026, meaning the agency had already\nconcluded its review before the market learned of the findings\nWhat the Decline Measured\n\nThe lawsuit contends that the stock price decline on March 24, 2026\nrepresented the removal of artificial inflation that had entered IBRX shares\nbeginning January 19, 2026 when the Executive Chairman appeared on a\nnationally broadcast podcast and made sweeping claims about ANKTIVA's\ncapabilities. According to the action, shareholders who purchased IBRX stock\nat prices inflated by these allegedly false statements suffered direct,\nquantifiable financial harm when the FDA's findings corrected the market's\nunderstanding of the drug's actual approved use and clinical evidence.\n\n\"When companies fail to disclose material information, shareholders may suffer\nsignificant losses. The sharp repricing of IBRX shares after the FDA Warning\nLetter suggests the market had been relying on promotional claims that the\nagency determined were false or misleading.\" -- Joseph E. Levi, Esq.\n\nCalculate your potential recovery in the IBRX securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669914-18&h=917685068&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185027%26wire%3D4&a=Calculate+your+potential+recovery+in+the+IBRX+securities+action)\n or call (212) 363-7500.\n\nABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi &\nKorsinsky has secured hundreds of millions of dollars for aggrieved\nshareholders. The firm has extensive expertise in complex securities\nlitigation and a team of over 70 employees. For seven consecutive years, Levi\n& Korsinsky has ranked in ISS Securities Class Action Services' Top 50\nReport. The last day to move for lead plaintiff is May 26, 2026.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: How much did IBRX stock drop? A: Shares fell approximately 21%, a decline\nof $1.98 per share, after the FDA Warning Letter regarding false and\nmisleading promotional communications about ANKTIVA became public. Investors\nwho purchased shares during the class period at artificially inflated prices\nmay be entitled to compensation.\n\nQ: When did ImmunityBio allegedly mislead investors? A: The class period runs\nfrom January 19, 2026 to March 24, 2026. The alleged fraud was revealed\nthrough the publicization of an FDA Warning Letter on March 24, 2026, causing\na significant stock decline.\n\nQ: What do IBRX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi\n& Korsinsky for a free, no-obligation evaluation at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\nNo immediate action is required to remain eligible as a class member.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-fda-allegedly-exposed-misleading-claims-levi--korsinsky-302749823.html\n(https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-fda-allegedly-exposed-misleading-claims-levi--korsinsky-302749823.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5ds3x7a","title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky","author":"PR Newswire","ticker":"IBRX","created":"2026-04-22T13:00:51.734Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nCritical Information: $1.98 Per Share Loss Quantifies Alleged Investor Damages\nAfter FDA Warning Letter\n\nNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds\npurchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities of a pending\nsecurities class action.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nTHE CASE: A class action seeks to recover damages for investors who purchased\nIBRX securities between January 19, 2026 and March 24, 2026.\n\nYOUR OPTIONS: You may be entitled to compensation without payment of any\nout-of-pocket fees. See if you can recover losses from your IBRX investment\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669914-18&h=3450116832&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185027%26wire%3D4&a=See+if+you+can+recover+losses+from+your+IBRX+investment)\n or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com\n(mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\n\nOn March 24, 2026, ImmunityBio shares lost $1.98 per share, falling 21% to\nclose at $7.42. The day prior, shares had traded as high as $9.40. The\ncollapse followed the publicization of an FDA Warning Letter that determined\nImmunityBio's promotional communications about its bladder cancer drug ANKTIVA\nwere false or misleading and misbranded the product in violation of federal\nlaw.\n\nThe March 24 Market Repricing\n\nThe market removed artificial inflation from IBRX shares after the FDA Warning\nLetter revealed that the Company's Executive Chairman had made claims about\nANKTIVA that the agency found to be unsupported by clinical data. The FDA\ndetermined that a TV advertisement and a January 19, 2026 podcast appearance\ncreated \"a misleading impression that Anktiva, a treatment for a certain type\nof bladder cancer, can cure and even prevent all cancer.\" The filing states\nthat the FDA called these violations \"concerning from a public health\nperspective\" because they \"grossly misrepresent the benefits of Anktiva.\"\n\nHow the Market Absorbed the Corrective Disclosure\n\n * IBRX shares traded at $9.40 on March 23, 2026, the last trading day before the\nFDA Warning Letter became public\n * Shares opened sharply lower on March 24 and closed at $7.42, a single-day loss\nof $1.98 per share\n * The 21% decline reflected the market's rapid reassessment of the Company's\npromotional claims about ANKTIVA\n * Bloomberg published an article titled \"ImmunityBio Plunges After Getting FDA\nWarning on Cancer Drug,\" amplifying the corrective information across\nfinancial media\n * The FDA letter was dated March 13, 2026, meaning the agency had already\nconcluded its review before the market learned of the findings\nWhat the Decline Measured\n\nThe lawsuit contends that the stock price decline on March 24, 2026\nrepresented the removal of artificial inflation that had entered IBRX shares\nbeginning January 19, 2026 when the Executive Chairman appeared on a\nnationally broadcast podcast and made sweeping claims about ANKTIVA's\ncapabilities. According to the action, shareholders who purchased IBRX stock\nat prices inflated by these allegedly false statements suffered direct,\nquantifiable financial harm when the FDA's findings corrected the market's\nunderstanding of the drug's actual approved use and clinical evidence.\n\n\"When companies fail to disclose material information, shareholders may suffer\nsignificant losses. The sharp repricing of IBRX shares after the FDA Warning\nLetter suggests the market had been relying on promotional claims that the\nagency determined were false or misleading.\" -- Joseph E. Levi, Esq.\n\nCalculate your potential recovery in the IBRX securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669914-18&h=917685068&u=https%3A%2F%2Fzlk.com%2Fcases%2Fimmunitybio-inc-lawsuit-submission-form%3Fprid%3D185027%26wire%3D4&a=Calculate+your+potential+recovery+in+the+IBRX+securities+action)\n or call (212) 363-7500.\n\nABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi &\nKorsinsky has secured hundreds of millions of dollars for aggrieved\nshareholders. The firm has extensive expertise in complex securities\nlitigation and a team of over 70 employees. For seven consecutive years, Levi\n& Korsinsky has ranked in ISS Securities Class Action Services' Top 50\nReport. The last day to move for lead plaintiff is May 26, 2026.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: How much did IBRX stock drop? A: Shares fell approximately 21%, a decline\nof $1.98 per share, after the FDA Warning Letter regarding false and\nmisleading promotional communications about ANKTIVA became public. Investors\nwho purchased shares during the class period at artificially inflated prices\nmay be entitled to compensation.\n\nQ: When did ImmunityBio allegedly mislead investors? A: The class period runs\nfrom January 19, 2026 to March 24, 2026. The alleged fraud was revealed\nthrough the publicization of an FDA Warning Letter on March 24, 2026, causing\na significant stock decline.\n\nQ: What do IBRX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi\n& Korsinsky for a free, no-obligation evaluation at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or (212) 363-7500.\nNo immediate action is required to remain eligible as a class member.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-fda-allegedly-exposed-misleading-claims-levi--korsinsky-302749823.html\n(https://www.prnewswire.com/news-releases/ibrx-investor-alert-immunitybio-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-fda-allegedly-exposed-misleading-claims-levi--korsinsky-302749823.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T13:00:51.803484085Z","server_sent_at_ms":1776862851803},"received_at":"2026-04-22T13:00:51.912Z","source_url":null},"analysis":{"id":"3502","press_release_id":"4900","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["securities fraud class action lawsuit filed","FDA Warning Letter alleges false and misleading promotional communications","stock dropped 21% on corrective disclosure","allegations that Executive Chairman made unsupported claims about drug curing and preventing all cancer"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced a securities class action lawsuit against ImmunityBio, alleging investors suffered losses due to misleading promotional claims about its bladder cancer drug ANKTIVA.\n\nThe lawsuit follows a 21% single-day stock decline on March 24, triggered by an FDA Warning Letter that found the company's promotional materials were false, misleading, and misbranded.\n\nThe class period covers purchases between January 19, 2026, and March 24, 2026, with the deadline to seek lead plaintiff appointment set for May 26, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Major legal headwind for IBRX as securities fraud suit cites FDA warning over exaggerated ANKTIVA claims."},"keyFigures":{"customDimensions":{"prior_close_high":"$9.40","post_decline_close":"$7.42","stock_drop_percent":"21%","stock_loss_per_share":"$1.98"}},"quotedText":"When companies fail to disclose material information, shareholders may suffer significant losses. The sharp repricing of IBRX shares after the FDA Warning Letter suggests the market had been relying on promotional claims that the agency determined were false or misleading.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky","role":"Esq., Levi & Korsinsky, LLP"}],"products":["ANKTIVA"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX","relationship":"defendant"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff counsel"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Bloomberg","relationship":"media"}],"dollarAmounts":[{"amount":"$1.98","context":"per share loss on March 24, 2026"},{"amount":"$9.40","context":"trading high on March 23, 2026"},{"amount":"$7.42","context":"closing price on March 24, 2026"}]},"materialImpact":{"score":5,"reasoning":"The announcement of a securities fraud class action lawsuit following a 21% stock decline triggered by an FDA Warning Letter is a high-impact, market-moving event involving allegations of misleading claims about the company's primary asset."},"tickerRelevance":{"others":[],"primary":"IBRX"},"eventTypeSecondary":["regulatory"]},"event_type":"legal_litigation","event_type_secondary":["regulatory"],"sentiment":"bearish","material_impact_score":5,"narrative":"Levi & Korsinsky announced a securities class action lawsuit against ImmunityBio, alleging investors suffered losses due to misleading promotional claims about its bladder cancer drug ANKTIVA.\n\nThe lawsuit follows a 21% single-day stock decline on March 24, triggered by an FDA Warning Letter that found the company's promotional materials were false, misleading, and misbranded.\n\nThe class period covers purchases between January 19, 2026, and March 24, 2026, with the deadline to seek lead plaintiff appointment set for May 26, 2026.","key_figures":{"customDimensions":{"prior_close_high":"$9.40","post_decline_close":"$7.42","stock_drop_percent":"21%","stock_loss_per_share":"$1.98"}},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky","role":"Esq., Levi & Korsinsky, LLP"}],"products":["ANKTIVA"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX","relationship":"defendant"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff counsel"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Bloomberg","relationship":"media"}],"dollarAmounts":[{"amount":"$1.98","context":"per share loss on March 24, 2026"},{"amount":"$9.40","context":"trading high on March 23, 2026"},{"amount":"$7.42","context":"closing price on March 24, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T17:42:45.820Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.229Z"}},"durationMs":27248,"modelName":"glm-4.7"}}